Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GHRL
REST API REST API
Homo sapiens
GHRL is differentially expressed in 66 experiments: 28 organism parts: stomach cardiac, stomach fundus, ... (26 more);, 31 disease states: normal, breast carcinoma, ... (29 more);, 21 cell types 131 cell lines 14 compound treatments and 31 other conditions.
Synonyms ghrelin, obestatin, MTLRP
Orthologs GHRL (Gallus gallus)   GHRL_BOVIN (Bos taurus)   Ghrl (Mus musculus)   Ghrl (Rattus norvegicus)   GHRL_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein tyrosine kinase activator activity, stored secretory granule, glucose metabolic process, elevation of cytosolic calcium ion concentration, regulation of excitatory postsynaptic membrane potential, axon, cytoplasm, regulation of cell proliferation, extracellular space, actin polymerization or depolymerization, negative regulation of apoptosis, hormone-mediated signaling pathway, G-protein coupled receptor protein signaling pathway, extracellular region, positive regulation of multicellular organism growth, G-protein-coupled receptor binding, anti-apoptosis, activation of MAPK activity, hormone activity, regulation of response to food, adult feeding behavior, response to hormone stimulus, dendrite development, endoplasmic reticulum lumen, negative regulation of tumor necrosis factor biosynthetic process, positive regulation of growth hormone secretion, negative regulation of interleukin-6 biosynthetic process, positive regulation of growth hormone receptor signaling pathway, positive regulation of response to food, negative regulation of circadian sleep/wake cycle, REM sleep, negative regulation of angiogenesis, growth hormone-releasing hormone activity, decidualization, gastric acid secretion, positive regulation of circadian sleep/wake cycle, non-REM sleep, negative regulation of interleukin-1 beta production, negative regulation of insulin secretion, response to estrogen stimulus, positive regulation of insulin secretion, negative regulation of inflammatory response, positive regulation of appetite, cartilage development, negative regulation of locomotion, positive regulation of cortisol secretion, growth hormone secretion, ghrelin receptor binding, positive regulation of protein tyrosine kinase activity, negative regulation of endothelial cell proliferation, cortisol secretion, positive regulation of corticotropin secretion, positive regulation of synapse assembly
InterPro Term Preproghrelin, Motilin_assoc, Motilin_ghrelin
UniProt Accession Q9UBU3, Q86YP8, A8DN24, Q5Y392, A2T3X3, A2T3X2, E7ESW0
Gene-Disease Assocation OBESITY
Search EB-eye ENSG00000157017
Show more properties
Experimental Factors
Organism part

studied in E-MTAB-37, E-GEOD-803, E-GEOD-18105, E-GEOD-7307, E-GEOD-3526, ... (6 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-MTAB-37, E-GEOD-5823, E-GEOD-12662, E-GEOD-19466, E-GEOD-6013, ... (10 experiments)

Factor Value U/D Experiments
C4II
1
E-MTAB-37
D341Med
1
E-MTAB-37
AGS
1
1
E-MTAB-37
Capan1
1
E-MTAB-37
BeWo
1
E-MTAB-37
SR
1
E-MTAB-37
125 more value(s).


Cell type

studied in E-GEOD-13987, E-GEOD-18811, E-GEOD-12662, E-GEOD-19069, E-TABM-34, ... (11 experiments)

Factor Value U/D Experiments
macrophage
1
E-GEOD-22373
monocyte
1
E-GEOD-22373
lung carcinoma
1
E-GEOD-17347
CD34 positive
1
E-GEOD-12662
T-ALL
1
E-GEOD-19069
neutrophil
1
E-GEOD-12662
15 more value(s).


Disease state

studied in E-GEOD-4290, E-GEOD-3307, E-GEOD-6338, E-MTAB-37, E-GEOD-1145, ... (12 experiments)

Factor Value U/D Experiments
benign prostatic hyperplasia
1
E-MEXP-1243
large cell lung carcinoma
1
E-MTAB-37
cervical carcinoma
1
E-MTAB-37
Moderate
1
E-GEOD-22148
anaplastic large cell lymphoma
1
E-GEOD-6338
clear cell renal carcinoma
1
E-TABM-282
25 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-6400, E-TABM-868, E-GEOD-15811, E-MEXP-2241, ... (7 experiments)

Factor Value U/D Experiments
Cxcl12
1
E-GEOD-7307
SDF
1
E-GEOD-7307
4-hydroxytamoxifen
1
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
unknown
1
E-GEOD-7307
bacterial endotoxin
1
E-GEOD-3284
8 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Clinical history
studied in E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-MTAB-37, E-GEOD-19348, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-22148

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-GEOD-17347

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-MEXP-1103, E-MEXP-2146

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-GEOD-3284, E-MEXP-1243, E-TABM-276, E-GEOD-16363, ... (7 experiments)

Karyotype
studied in E-GEOD-12662

Material type
studied in E-GEOD-9171

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19246

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-21374

Stimulation
studied in E-GEOD-20114

Survival time
studied in E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Processing time: 0.305 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM